These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29728204)

  • 1. Chronic Lymphocytic Leukemia: Diagnosis and Treatment.
    Strati P; Jain N; O'Brien S
    Mayo Clin Proc; 2018 May; 93(5):651-664. PubMed ID: 29728204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.
    Marini BL; Samanas L; Perissinotti AJ
    J Oncol Pharm Pract; 2017 Oct; 23(7):502-517. PubMed ID: 27357816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.
    Hilal T; Gea-Banacloche JC; Leis JF
    Blood Rev; 2018 Sep; 32(5):387-399. PubMed ID: 29571669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia.
    Hanna KS
    J Oncol Pharm Pract; 2020 Jan; 26(1):146-155. PubMed ID: 31189420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic lymphocytic leukaemia.
    Hallek M; Shanafelt TD; Eichhorst B
    Lancet; 2018 Apr; 391(10129):1524-1537. PubMed ID: 29477250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
    Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
    Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
    Cheson BD
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in chronic lymphocytic leukaemia.
    García Vela JA; García Marco JA
    Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
    Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
    Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
    García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
    Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies].
    Kojima K
    Rinsho Ketsueki; 2020; 61(9):1275-1280. PubMed ID: 33162526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
    Wierda WG; Kipps TJ; Keating MJ
    J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017.
    Weide R; Feiten S; Chakupurakal G; Friesenhahn V; Kleboth K; Köppler H; Lutschkin J; van Roye C; Thomalla J; Heymanns J
    Leuk Lymphoma; 2020 Mar; 61(3):557-566. PubMed ID: 31682164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of chronic lymphocytic leukemia: potential directions from ASH 2017.
    Molica S
    Expert Rev Hematol; 2018 Jun; 11(6):481-486. PubMed ID: 29791237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.